Bryan Lenneman’s research interests include utilizing synthetic biology to develop novel therapeutics against diseases associated with dysbiosis of the human gut microbial community.

March 30, 2023

Rima Mycynek

We were pleased to hear from Bryan Lenneman, Ph.D., today on “Engineering Phages as Novel Antimicrobials Targeting Gram-Negative Pathogens.” Dr. Lenneman is a Research Fellow at Massachusetts General Hospital whose research interests include utilizing synthetic biology to develop novel therapeutics against diseases associated with dysbiosis of the human gut microbial community.

Dr. Lenneman’s work focuses on engineering bacteriophages as an alternative to conventional antibiotics for the removal of pathogenic bacteria and on developing probiotic bacteria as therapeutic additives to the gut microbiome.

Dr. Lenneman is a Research Fellow in MGH’s Christina Faherty Lab and was previously a Postdoctoral Associate in the Timothy Lu lab at MIT from 2019-2022. He obtained his Ph.D. in Genetics, Genomics, and Systems Biology at The University of Chicago in 2019.

Video: Engineering Phages as Novel Antimicrobials Targeting Gram-Negative Pathogens – Massachusetts General Hospital’s Bryan Lenneman, Ph.D.